Azenta, Inc. (NASDAQ:AZTA) CFO Sells $28,529.84 in Stock

Azenta, Inc. (NASDAQ:AZTA) CFO Herman Cueto sold 712 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $40.07, for a total value of $28,529.84. Following the sale, the chief financial officer now directly owns 23,892 shares of the company’s stock, valued at approximately $957,352.44. This represents a 2.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Herman Cueto also recently made the following trade(s):

• On Thursday, October 17th, Herman Cueto sold 1,595 shares of Azenta stock. The stock was sold at an average price of $43.68, for a total transaction of $69,669.60.

Azenta Stock Performance

Azenta stock opened at $45.16 on Friday. Azenta, Inc. has a twelve month low of $38.82 and a twelve month high of $69.16. The firm has a market cap of $2.21 billion, a PE ratio of -15.21 and a beta of 1.48. The firm’s 50 day moving average price is $45.22 and its two-hundred day moving average price is $50.08.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.08. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. The business had revenue of $170.00 million for the quarter, compared to the consensus estimate of $169.66 million. During the same period in the prior year, the business posted $0.13 earnings per share. Azenta’s revenue for the quarter was down 1.2% compared to the same quarter last year. Equities analysts anticipate that Azenta, Inc. will post 0.4 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on AZTA. Evercore ISI lowered their price objective on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Needham & Company LLC dropped their price target on Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Azenta presently has a consensus rating of “Hold” and an average target price of $63.60.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AZTA. Hantz Financial Services Inc. acquired a new stake in shares of Azenta during the 2nd quarter valued at about $30,000. Farther Finance Advisors LLC raised its position in Azenta by 20.0% during the third quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock valued at $74,000 after acquiring an additional 256 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Azenta by 150.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock valued at $84,000 after acquiring an additional 955 shares during the last quarter. Lazard Asset Management LLC bought a new stake in Azenta in the first quarter worth approximately $130,000. Finally, Acadian Asset Management LLC increased its stake in shares of Azenta by 24.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock worth $143,000 after purchasing an additional 471 shares during the last quarter. 99.08% of the stock is owned by institutional investors and hedge funds.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.